IP Library Granted Patent US 10,138,466
Granted Patent B2
US 10,138,466 · App. 15/705,896 · Granted Nov 27, 2018

Compositions and methods for differentiating stem cells into cell populations comprising beta-like cells

Inventors: Xiaofang Xu (Park Ridge, IL); Jon Odorico (Park Ridge, IL); Erik Forsberg (Park Ridge, IL); Amber A. Mael (Madison, WI)
Assignee: REGENERATIVE MEDICAL SOLUTIONS, INC.
C12N5/0676A61K9/1652A61K9/5036A61K35/39A61K45/06G01N33/507H05K999/99A61K35/545C12N2500/05C12N2500/22C12N2500/25C12N2500/38C12N2500/44C12N2500/90C12N2501/01C12N2501/105C12N2501/11C12N2501/115C12N2501/117C12N2501/155C12N2501/16C12N2501/33C12N2501/335C12N2501/385C12N2501/395C12N2501/40C12N2501/727C12N2501/91C12N2501/998C12N2501/999C12N2506/02C12N2506/45
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,138,466
App. No.
15/705,896
Granted
Nov 27, 2018
Kind
B2
Abstract

Methods, kits, compositions, and systems are provided for culturing pluripotent stem cells to produce populations of cells comprising beta-like cells (e.g., pancreatic lineage, glucose-responsive, and/or insulin-producing). In particular, culture conditions are provided that result in the generation of beta-like cells from a starting culture of human pluripotent stem cells.

Claims (17)

1. A kit, comprising:

differentiation medium comprising a B27 serum-free medium, IGF I, IGF II, FGF7, insulin, nicotinamide, exendin-4, ALK5i II, and forskolin.

2. The kit of claim 1 , wherein said kit further comprises a chemically defined medium, basic fibroblast growth factor, Activin A, and BMP4.

3. The kit of claim 1 , wherein said kit further comprises chemically defined insulin, transferrin and selenium (ITS) medium, FGF7, and nicotinamide.

4. The kit of claim 1 , wherein said kit further comprises a chemically defined ITS medium; retinoic acid; Noggin; and nicotinamide.

5. The kit of claim 1 , wherein said kit further comprises chemically defined ITS medium, retinoic acid, and Noggin.

6. The kit of claim 1 , wherein said kit further comprises a serum-free medium, ALK5, Forskolin, ZnSO4, T3, B27, heparin, and antioxidant, Warfarin, and a P13 kinase inhibitor.

7. The kit of claim 1 , wherein said kit further comprises LY294002.

8. The kit of claim 1 , wherein said kit further comprises EGF.

9. The kit of claim 1 , wherein said kit further comprises Warfarin.

10. The kit of claim 1 , wherein said kit further comprises chemically defined ITS medium, FGF7, and nicotinamide.

11. The kit of claim 1 , wherein said kit further comprises a chemically defined medium, basic fibroblast growth factor, Activin A, BMP4, chemically defined insulin, transferrin and selenium (ITS) medium, FGF7, retinoic acid, Noggin, nicotinamide, B27 serum-free medium, IGFI, FGF7, insulin, exendin-4, forskolin, a serum-free medium, ALK5, ZnSO4, T3, B27, EGF, heparin, LY294002, an antioxidant, Warfarin, and a P13 kinase inhibitor.

12. The kit of claim 1 , wherein said kit further comprises an extracellular matrix.

13. The kit of claim 1 , wherein said kit comprises one or more containers.

14. The kit of claim 1 , wherein said kit comprises two or more containers.

15. The kit of claim 1 , wherein said kit comprises a single container.

16. The kit of claim 1 , wherein said kit further comprises, in at least two additional containers, a chemically defined medium, basic fibroblast growth factor, Activin A, BMP4, chemically defined insulin, transferrin and selenium (ITS) medium, FGF7, retinoic acid, Noggin, nicotinamide, B27 serum-free medium, IGFI, FGF7, insulin, exendin-4, forskolin, a serum-free medium, ALK5, ZnSO4, T3, B27, EGF, heparin, LY294002, an antioxidant, Warfarin, and a P13 kinase inhibitor.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 21, 2017
From: XU, XIAOFANG; ODORICO, JON; FORSBERG, ERIK; MAEL, AMBER A.
To: REGENERATIVE MEDICAL SOLUTIONS, INC.
Reel/Frame 043655/0547 →
Continuity (5)
Continuation 15187345 · Jun 20, 2016
Continuation 14858465 · Sep 18, 2015
Provisional Application 62173759 · Jun 10, 2015
Provisional Application 62052894 · Sep 19, 2014
Related Publication 20180087033A1 · Mar 29, 2018